0000000000074355

AUTHOR

G. Porzio

showing 5 related works from this author

Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.

2010

The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain.This was a nonrandomized, open-label, uncontrolled study in fifty consecutive opioid-naive patients with advanced cancer and moderate pain. TD fentanyl was initiated at a dose of 12 µg/h. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD fentanyl doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated.Thirty-one patients completed all 4 weeks of the study. Pain control was achieved within a me…

MaleTransdermal patchCancer pain; Opioids; Trandermal fentanyl; Aged; Analgesia; Analgesics Opioid; Dose-Response Relationship Drug; Female; Fentanyl; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms; Pain; Palliative Care; Transdermal Patch; Medicine (all)medicine.medical_treatmentPainTransdermal PatchOpioidFentanylDose-Response RelationshipNeoplasmsmedicineHumansCancer painAdverse effectNeoadjuvant therapyTransdermalAgedAnalgesicsDose-Response Relationship Drugbusiness.industryMedicine (all)Palliative CareGeneral MedicineMiddle AgedNeoadjuvant TherapyOpioidsClinical trialAnalgesics OpioidFentanylTolerabilityTrandermal fentanylAnesthesiaFemaleDrugAnalgesiaCancer painbusinessmedicine.drugCurrent medical research and opinion
researchProduct

TRIPLET SCHEDULE OF WEEKLY 5-FLUOROURACIL AND ALTERNATING IRINOTECAN OR OXALIPLATIN IN ADVANCED COLORECTAL CANCER: A DOSE-FINDING AND PHASE II STUDY.

2010

A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association. The following weekly schedule was administered: irinotecan, days 1 and 15; oxaliplatin, days 8 and 22; 5-fluorouracil (5-FU) over 12-h (from 10:00 p.m. to 10:00 a.m.) timed flat infusion, days 1-2, 8-9, 15-16 and 22-23, every 4 weeks. Dose- finding and phase II study were planned. Thirteen patients were enrolled in the dose-finding study and 23 in the phase II study. The recommended doses of our study are: irin…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsMaximum Tolerated DoseOrganoplatinum CompoundsSettore MED/06 - Oncologia Medica5-FluorouracilPhases of clinical researchIrinotecanGastroenterologyInternal medicineCPT-11Antineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdvanced colorectal cancerAgedDose-Response Relationship Drugbusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseOxaliplatinIrinotecanOxaliplatinSurvival RateRegimenTreatment OutcomeOncologyTolerabilityFluorouracilLymphatic MetastasisToxicityl-OHPCamptothecinFemaleFluorouracilbusinessColorectal NeoplasmsFebrile neutropeniamedicine.drug
researchProduct

Low morphine doses in opioid-naive cancer patients with pain

2006

Cancer pain can be managed in most patients through the use of the analgesic ladder proposed by the World Health Organization. Recent studies have proposed to skip the second "rung" of the ladder by using a so-called "strong" opioid for moderate pain. However, usual doses of strong opioids commonly prescribed for the third rung of the analgesic ladder may pose several problems in terms of tolerability in opioid-naive patients. The aim of this multicenter study was to evaluate the efficacy and tolerability of very low doses of morphine in advanced cancer patients no longer responsive to nonopioid analgesics. A sample of 110 consecutive opioid-naive patients with moderate-to-severe pain were …

AdultMalePainWHO method cancer pain opioids morphineOpioidDose-Response RelationshipQuality of lifeNeoplasmsWHO methodMedicineHumansCancer painOpioid peptideGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedAnalgesicsDose-Response Relationship DrugCancer pain; Morphine; Opioids; WHO method; Adult; Aged; Analgesics Opioid; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Morphine; Neoplasms; Pain; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Morphinebusiness.industryCancerMiddle Agedmedicine.diseaseAnalgesics OpioidClinical trialOpioidsTreatment OutcomeAnesthesiology and Pain MedicineTolerabilityOpioidNeurologyAnesthesiaMorphineFemaleNeurology (clinical)DrugbusinessCancer painmedicine.drug
researchProduct

From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters

2006

Recently, chemoprevention trials have demonstrated the efficacy of preventive medical treatment (PMT) in reducing breast cancer (BC) detection rates in at-risk affected and unaffected women selected according to clinical and/or familial risk criteria, particularly with the use of tamoxifen (TAM). Major concerns limiting the routine use of TAM are the questionable benefit/risk ratio and poor patient compliance, which justify the studies undertaken to determine the efficacy of aromatase inhibitors (AIs) with respect to TAM. Issues such as therapy duration, impact on survival, incidence of side-effects and which subsets benefit most from treatment, still remain unsolved. Therefore, only ER+ BC…

Oncologymedicine.medical_specialtymedicine.medical_treatmentGenes BRCA2Genes BRCA1Breast NeoplasmsBreast cancerRisk FactorsInternal medicinemedicineHumansGenetic Predisposition to DiseaseAromataseskin and connective tissue diseasesbiologybusiness.industryIncidence (epidemiology)Estrogen AntagonistsHematologymedicine.diseaseClinical trialTamoxifenOncologyChemotherapy AdjuvantRelative riskbiology.proteinHormonal therapyFemalebusinessAdjuvantTamoxifenmedicine.drugAnnals of Oncology
researchProduct

Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational stu…

2009

OBJECTIVE: The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) buprenorphine patches in opioid-naive patients with cancer pain. METHODS: This was a nonrandomized, open-label, uncontrolled study in consecutive opioid-naive patients with advanced cancer and moderate pain. TD buprenorphine was initiated at a dose of 17.5 microg/h (0.4 mg/d), with patch changes every 3 days. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD buprenorphine doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated. RESULTS: Thi…

Malecancer painPainOpioidUncontrolled Studytransdermal buprenorphine cancer pain uncontrolled observational studyDose-Response RelationshipNeoplasmsmedicineHumansPharmacology (medical)Adverse effectAgedPain MeasurementIntractablePharmacologyAnalgesicsbusiness.industryopioidsCancermorphineMiddle Agedbuprenorphine; cancer pain; morphine; opioids; Administration Cutaneous; Aged; Analgesics Opioid; Buprenorphine; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pain Intractable; Quality of Life; Pharmacology; Pharmacology (medical)buprenorphinemedicine.diseaseClinical trialCutaneousTolerabilityAnesthesiaAdministrationQuality of LifeMorphineFemaleDrugCancer painbusinessmedicine.drugBuprenorphineClinical Therapeutics
researchProduct